Reduced initial Pazopanib dosing strategy for recurrent, advanced, or metastatic sarcoma: A single center experience [0.03%]
帕唑帕尼减量策略治疗复发、晚期或转移性肉瘤的单中心经验报告
Chaeyeong Jang,Kevin Chen,Samantha A Armstrong et al.
Chaeyeong Jang et al.
IntroductionPazopanib is a treatment option for patients who have advanced or metastatic soft tissue sarcoma. Although the FDA label recommends pazopanib 800 mg q24h as the initial dose, the starting dose in clinical practice can range from...
Pharmacist-led anticoagulation care in cancer: Associations with bleeding and VTE recurrence [0.03%]
药剂师主导的癌症抗凝护理与出血和VTE复发的关系
Sajjad Ullah,Inayat Ur Rehman,Javeria Khalid et al.
Sajjad Ullah et al.
ObjectivesVenous thromboembolism (VTE) is a major complication in cancer patients, resulting in heightened mortality and morbidity. Managing recurrence of VTE or risk of bleeding is a major challenge among cancer patients receiving anticoag...
Evaluating the incidence of thrombosis in patients with concurrent second-generation androgen receptor inhibitor therapy and direct oral anticoagulants: A retrospective chart review [0.03%]
评估第二代雄激素受体抑制剂联合直接口服抗凝药治疗患者的血栓事件发生率：回顾性病历分析
Zachary Larson,Cassia Griswold
Zachary Larson
Introduction: Many patients with prostate cancer have an indication for anticoagulation. This presents a pharmacokinetic dilemma as enzalutamide and apalutamide have significant effects on the metabolism of direct oral an...
Primary central nervous system lymphoma: Evolving treatment strategies to achieve improved long-term disease control [0.03%]
Moza Hamoud,Victor M Samperio,Ion Codreanu et al.
Moza Hamoud et al.
ObjectiveDespite high initial response rates to chemotherapy, long-term disease control in primary central nervous system lymphoma (PCNSL) remains challenging, with high relapse rates and no universally accepted standard for induction or co...
Immune checkpoint inhibitors for the treatment of cancer in people living with HIV [0.03%]
人类免疫缺陷病毒(HIV)感染者的免疫检查点抑制剂癌症治疗
Sara Rodríguez-Tierno,Jorge Fernández-Fradejas,Manuel Vélez-Díaz-Pallarés et al.
Sara Rodríguez-Tierno et al.
ObjectivesTo describe the impact of immune checkpoint inhibitors (ICPi) in infection control in people living with HIV (PLWHIV) and to explore their safety compared with a matched cohort of people living without HIV (PLWOHIV). Secondary, to...
Pediatric pharmaceutical forms in oncology: A review of galenic challenges, difficulties encountered in hospital practice, and perspectives offered by new technologies [0.03%]
儿科肿瘤药剂形式的挑战、医院实践中遇到的问题及新技术提供的展望评审文章
Seham El Deeb,Ismail Bennani,Ali C Chefchaouni et al.
Seham El Deeb et al.
ObjectiveTo review the pharmaceutical challenges associated with pediatric anticancer formulations and discuss current limitations, hospital practice difficulties, and emerging technological strategies to improve safety, accuracy, and accep...
Potential impact of clinical pharmacist services on mitigating oral and nutritional complications and quality of life in hospitalized patients with hematological malignancies [0.03%]
临床药剂师服务对住院血液系统恶性肿瘤患者口腔和营养并发症及生活质量的潜在影响
Aygül Köseoğlu,Anmar Al-Taie,Mesut Sancar et al.
Aygül Köseoğlu et al.
BackgroundsThe prevalence of oral and malnutrition disorders is quite high in patients with hematological malignancies which may complicate cancer management resulting in poor prognosis, lower quality of life (QoL) and more deterioration of...
Real-world effectiveness of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and advanced melanoma at BC Cancer [0.03%]
在BC癌症中心接受辅助和晚期黑色素瘤治疗的患者中，每两周一次（Q2W）与每四周一次（Q4W）纳武利尤单抗的有效性比较研究
Ruishen Yu,Kiran Gill,Shirley St Yeung et al.
Ruishen Yu et al.
IntroductionNivolumab has demonstrated promising survival outcomes in melanoma. Original dosing was 3 mg/kg (maximum 240 mg) intravenously (IV) every two weeks (Q2 W). Based on pharmacokinetic and pharmacodynamic studies demonstrating simil...
Characterizing pharmacist impact in maintenance therapy for adolescent and young adults with acute lymphoblastic leukemia treated with CALGB 10403 protocol [0.03%]
CALGB 10403方案治疗的急性淋巴细胞白血病青少年和年轻成年患者维持治疗中药师的作用特征分析
Cami Andreini,Brian Lam,Taylor Dennison et al.
Cami Andreini et al.
IntroductionCancer and Leukemia Group B (CALGB) 10403 is a pediatric-inspired treatment protocol for adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients. During Course V maintenance, patients receive mercaptopurine ...